Gain Therapeutics, Inc. 8-K

What Happened
Gain Therapeutics, Inc. announced its financial results for the quarter ended March 31, 2026 and provided a business update via a press release dated May 11, 2026. The company filed a Current Report on Form 8-K (Item 2.02) on May 11, 2026 to disclose these quarterly results; the press release is furnished as Exhibit 99.1 to the filing. The Form 8-K was signed by CEO Gene Mack.

Key Details

• Press release announcing Q1 2026 results and business update issued and furnished to the SEC on May 11, 2026 (Exhibit 99.1).
• Reporting period: quarter ended March 31, 2026.
• Disclosure made on Form 8-K under Item 2.02 (Results of Operations and Financial Condition).
• Filing signed by Chief Executive Officer Gene Mack.

Why It Matters
This filing signals Gain Therapeutics is disclosing its quarterly earnings and operational status — information investors use to assess recent performance, cash runway, and progress on development or commercialization milestones. Retail investors should read the furnished press release and the company’s periodic reports (e.g., the next 10-Q) for detailed figures on revenue, expenses, cash position, and any forward-looking guidance or material business developments referenced in the update.